Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy.
Antibody-drug conjugate (ADC), a novel class of antineoplastic agents, combines tumor-specific targeting with potent cytotoxic activity. In recent years, ADC has achieved notable advances in the treatment of non-small cell lung cancer (NSCLC), particularly within therapeutic sequencing after failure...
| Publicado en: | Chinese Journal of Lung Cancer Vol. 28; no. 9; pp. 710 - 721 |
|---|---|
| Autores principales: | , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Chinese Journal of Lung Cancer
Sep2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189649761&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 189649761 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10093419 9014 jtl: Chinese Journal of Lung Cancer issn: 10093419 maglogo: N pubinfo: dt: Sep2025 vid: 28 iid: 9 pid: 54191 pub: Chinese Journal of Lung Cancer artinfo: ui: 189649761 189649761 189649761 10.3779/j.issn.1009-3419.2025.101.14 189649761 ppf: 710 ppct: 11 formats: fmt: @attributes: type: P tig: atl: Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy. aug: au: LI, Honglin JING, Yawan SUN, Jiayi XU, Jing LI, Yalun affil: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Net work, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China sug: subj: Patient Safety Evaluation Drug Efficacy Evaluation Antibodies Therapeutic Use Carcinoma, Non-Small-Cell Lung Drug Therapy Antibodies Adverse Effects Drug Design Tumor Markers, Biological Analysis Antineoplastic Agents, Combined Treatment Failure Drug Resistance, Neoplasm Lung Diseases, Interstitial Drug Therapy Cell Physiology Drug Effects Antibodies Immunology HER-2-neu Oncogene Drug Effects Trastuzumab Administration and Dosage Clinical Trials Treatment Outcomes Antibodies, Monoclonal Administration and Dosage Docetaxel Administration and Dosage Antibodies, Monoclonal Adverse Effects Tyrosine Kinase Inhibitors Therapeutic Use Platinum Therapeutic Use Overall Survival Evaluation Progression-Free Survival Evaluation ab: Antibody-drug conjugate (ADC), a novel class of antineoplastic agents, combines tumor-specific targeting with potent cytotoxic activity. In recent years, ADC has achieved notable advances in the treatment of non-small cell lung cancer (NSCLC), particularly within therapeutic sequencing after failure of first-line therapy or the emergence of resistance. This paper will systematically review the efficacy and safety evidence of representative ADC in NSCLC, and further to discuss progress and challenges in ADC structural optimization, toxicity management, biomarker identification, and combination strategies, aiming to provide a comprehensive theoretical foundation and practical reference for clinical practice and future research. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: Chinese refInfo: holdings: @attributes: islocal: N |
|---|